http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019053115-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523523e4857f980c860a0d49e77ed0ec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-26 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2018-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77000fa66a64b192ffbe084abff7fbef |
| publicationDate | 2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019053115-A1 |
| titleOfInvention | USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS |
| abstract | A method of monitoring therapy, including prognosis, risk assessment and / or stratification of the risk of a subsequent adverse event for a patient's health, including providing a sample of said patient the patient has been diagnosed as critically ill and medical treatment has been initiated, the sample being isolated from the patient after diagnosis and initiation of treatment; determining a level of proadrenomedullin (proADM) or a fragment or fragments thereof in said sample, said level of proADM or fragment or fragments thereof being correlated with the probability of a subsequent adverse event for the health of said patient. In a preferred embodiment, the invention relates to a method further comprising determining a level of procalcitonin (PCT) or fragment or fragments thereof in a sample isolated from the patient. Preferably, a method according to the present invention is to determine a level of procalcitonin (PCT) or a fragment or fragments thereof in a first isolated sample of the patient, said first sample being isolated at the diagnostic time point. and initiating a treatment (time point 0) or before it; determining a level of PCT or fragment or fragments thereof in a second isolated sample of said patient after diagnosis and initiation of treatment; and determining whether a difference in the level of PCT or a fragment or fragments thereof in the second sample is evident relative to the level of PCT or a fragment or fragments thereof in the first sample. |
| priorityDate | 2017-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1420.